Table 2.

Parameters of pCR, DFS and OS between the experimental and the standard regimens

Trial [Ref.]	Patients, n	Schedule	pCR rate (experimental vs. standard)	DFS (experimental vs. standard)	OS (experimental vs standard)
AGO 1 [12]	668	ddEP→CMF vs. EP→CMF	ypT0, ypN0/ pNx: 18% vs. 10% (p = sig)	5 years: 70% vs. 59%	5 years: 83% vs. 77%
GeparDuo [13]	913	ADOC AC-DOC	7% vs. 14% P = 0.0011	not reported	not reported
Prepare [14]	736	ddET→CMF EC-T	ypT0, ypN0/ pNx: 18% vs. 12% p = sig	3 years: 78.8% vs. 75.8% p= ns.
EORTC-NCIC-SAKK [16]	448	diEC CEF	clinical complete response 26.5% vs. 31.3% pCR not reported	5.5 years: 33.7 months vs. 34 months p = ns	5.5 years 51% vs. 53% p = ns
Baldini [17]	150	ddCEF q2w CEF q3w	ypT0, ypN0, ypTis, ypN0: 4.1 vs. 2.6 p = ns.	60% vs 58% p = ns.	5 years: 54% vs. 52% p = ns.
SWOG 0012 [21]	372	12× ddA→12×P 5× A→12× P	ypT0, ypN0/ pNx: p = ns	p = ns	p =ns
GeparSixto [23, 24]	595	18× P 80 q1w+NPLD 20 q1w +/- Cb AUC 1.5 q1w	all: 36.9% PMCb 43.7% p = ns. in TNBC: PM 36.9% PMCb 53.2%, p = 0.005 in HER2 pos: PM 36.8% PMCb 32.8%, p = 0.6	DFS after 3 years -F PMCb vs. PM all: 84.7 vs. 81.0, p = 0.31 HER2 pos.: 86.7 vs. 83.4, p =0.37 TNBC: 85.8 vs.76.1, p =0.03	not published

pCR = pathological complete response, DFS = disease-free survival, OS = overall survival, E = epirubicin, P = paclitaxel, C = cyclosphosphamide, M = methotrexate, F = 5-fluorouracil, A = adriamycin, ns = not significant, sig = significant, vs = versus, DOC = docetaxel, M = non-pegylated liposomal doxorubicin, Cb = carboplatin, Trast = trastuzumab, Lap = lapatinib, d = day.